Results 151 to 160 of about 40,704 (273)

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs

European Journal of Human Genetics, 2021
J. Brouwer, M. Nijenhuis, Bianca Soree, H. Guchelaar, J. Swen, R. V. van Schaik, J. Weide, G. Rongen, Anne M Buunk, Nienke J. de Boer-Veger, E. Houwink, R. van Westrhenen, B. Wilffert, V. Deneer, H. Mulder   +14 more
semanticscholar   +1 more source

Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies

European Neuropsychopharmacology, 2018
Cytochrome (CYP) P450 enzymes have a primary role in antidepressant metabolism and variants in these polymorphic genes are targets for pharmacogenetic investigation.
C. Fabbri, K. Tansey, R. Perlis, J. Hauser, N. Henigsberg, W. Maier, O. Mors, A. Placentino, M. Rietschel, D. Souery, G. Breen, C. Curtis, Sang-Hyuk Lee, S. Newhouse, Hamel Patel, M. O’Donovan, G. Lewis, G. Jenkins, R. Weinshilboum, A. Farmer, K. Aitchison, I. Craig, P. McGuffin, K. Schruers, J. Biernacka, R. Uher, C. Lewis   +26 more
semanticscholar   +1 more source

Opportunities and Challenges of Population Pharmacogenomics

Annals of Human Genetics, EarlyView.
ABSTRACT Pharmacological responses can vary significantly among patients from different ethnogeographic backgrounds. This variability can, at least in part, be attributed to population‐specific genetic patterns in genes involved in drug absorption, distribution, metabolism, and excretion, as well as in genes associated with drug‐induced toxicity ...
Yitian Zhou, Yoomi Park, Mahamadou D. Camara, Volker M. Lauschke   +3 more
wiley   +1 more source

Association of CYP2C19*2 polymorphisms and high on-treatment platelet reactivity in acute myocardial infarction or coronary artery in-stent restenosis patients during dual antiplatelet therapy

Medicine in Drug Discovery, 2020
Objective: Cytochrome CYP2C19 mutant allele is associated with high on-treatment platelet reactivity (HTPR) after standard clopidogrel treatment, which is accompanied by an increased risk of ischemic events. This study assesses the association of CYP2C19
Yawei Yang, Wei Zhang, Pan Li, Ying Gu, Liping Ma, Min Fan   +5 more
doaj  

Genomic Ancestry, CYP2D6, CYP2C9, and CYP2C19 Among Latin Americans

Clinical pharmacology and therapy, 2019
We present the distribution of CYP2D6, CYP2C9, and CYP2C19 variants and predicted phenotypes in 33 native and admixed populations from Ibero‐America (n > 6,000) in the context of genetic ancestry (n = 3,387).
F. Rodrigues-Soares, E. Peñas-Lledó, E. Tarazona-Santos, M. Sosa-Macías, E. Terán, M. López-López, I. Rodeiro, Graciela Moya, L. R. Calzadilla, R. Ramírez-Roa, M. Grazina, F. Estévez-Carrizo, R. Barrantes, A. Llerena   +13 more
semanticscholar   +1 more source

The NDE1 genomic locus can affect treatment of psychiatric illness through gene expression changes related to microRNA-484 [PDF]

, 2017
Genetic studies of familial schizophrenia in Finland have observed significant associations with a group of biologically related genes, DISCI1, NDE1,NDEL1, PDE4B and PDE4D, the 'DISCI network'. Here, we use gene expression and psychoactive medication use
Bradshaw, Nicholas J., Cannon, Tyrone D., Haukka, Jari, Hennah, William, Lonnqvist, Jouko, Ortega-Alonso, Alfredo, Pankakoski, Maiju, Paunio, Tiina, Sinha, Vishal, Suvisaari, Jaana, Therman, Sebastian, Torniainen-Holm, Minna, Ukkola-Vuoti, Liisa, Zheutlin, Amanda B.   +13 more
core   +3 more sources

Embedding Pharmacogenetics Into Clinical Practice to Improve Patient Outcomes

Annals of Human Genetics, EarlyView.
ABSTRACT Pharmacogenomics, the use of germline genomic data to guide prescription to improve effective and safer medication, holds promise as a clinical intervention. To date in most health systems, there has been limited uptake of pharmacogenomic testing confined to a few single drug–gene associations.
John Henry McDermott, Videha Sharma, Jessica Keen, William Gerard Newman   +3 more
wiley   +1 more source

CYP2C19*2 polimorfismo y resistencia a clopidogrel [PDF]

Archivos de Cardiología de México, 2021
Viroj Wiwanitkit, Beuy Joob
openaire   +4 more sources

METTL3-mediated methylation of CYP2C19 mRNA may aggravate clopidogrel resistance in ischemic stroke patients

Open Medicine
N6-methyladenosine (m6A) is the most frequently occurring interior modification in eukaryotic messenger RNA (mRNA), and abnormal mRNA modifications can affect many biological processes.
Tan Quandan, Yang Le, Yuan Shanshan, Zheng Danni, Lin Yapeng, Chen Kejie, He Ying, Chen Shuntian, Hao Junli, Dai Jin, He Song, Mao Fengkai, Leng Xinyi, Jiang Haisong, Yang Jie   +14 more
doaj   +1 more source

Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6.

Pharmacogenomics (London), 2017
Currently, most guidelines on drug-drug interaction (DDI) neither consider the potential effect of genetic polymorphism in the strength of the interaction nor do they account for the complex interaction caused by the combination of DDI and drug-gene ...
M. A. Bahar, D. Setiawan, E. Hak, B. Wilffert   +3 more
semanticscholar   +1 more source